News and Trends 25 Mar 2025 AbbVie and Genmab: Can a legal battle break a billion-dollar bond? As AbbVie accuses Genmab of unlawfully using proprietary ADC technology, find out about their collaboration and the dispute opposing them. March 25, 2025 - 5 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2022 Scancell signs agreement with Genmab Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer and infectious disease, has signed a licensing agreement with Genmab, an international biotechnology company, to develop and commercialize a Scancell investigational anti-glycan monoclonal antibody into novel therapeutic products. Genmab has been granted the exclusive right to develop and commercialize the Scancell antibody […] October 26, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2022 Oxford BioTherapeutics enters into antibody agreement with Genmab Oxford BioTherapeutics (OBT) says Genmab has licensed a novel antibody related to one of OBT’s IO programs. The target was discovered using Oxford BioTherapeutics’ OGAP drug discovery platform, which incorporates one of the world’s largest proteomic databases, integrating clinical, experimental and expression data. Under the terms of the agreement, Genmab will be responsible for the […] October 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jul 2022 License submitted to FDA for drug to help those with large B-cell lymphoma A biologics license application has been submitted to the US Food and Drug Administration (FDA) for an antibody to treat patients with B-cell lymphoma. Genmab A/S is a biotechnology company that says its core purpose is to improve the lives of people with cancer. Recently it announced its intent to submit the application for subcutaneous […] July 1, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Best in Biotech 20 Dec 2021 The Billion-Euro European Biotech Companies in 2022 Here’s a list of the public European biotech companies that are worth more than a billion euros in 2022. European biotech is growing steadily and this year we welcome a few new names to the list of billion-euro biotechs. However, we also had to say goodbye to some of them, including Cellectis, Autolus, and Orchard […] December 20, 2021 - 12 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email
News and Trends 25 May 2021 Delayed IPOs and Market Drops Batter Biotech Stocks Stock markets worldwide have experienced painful instability in the last few months. As a result, the European biotech market has seen stock prices falling and IPOs postponed. The Covid-19 pandemic was a major disruption for stock markets across the globe at the start of 2020. However, markets like Euronext and the tech-focused Nasdaq rallied and […] May 25, 2021 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 11 May 2021 ADC Approval Buoys Spirits in Cancer Treatment Space The FDA recently approved an antibody-drug conjugate drug from ADC Therapeutics as a treatment for blood cancer. This has given a major confidence boost to other European companies in the field as the deal mill picks up speed. Last month, ADC Therapeutics in Switzerland broke into the mainstream when its lead candidate Zynlonta received FDA […] May 11, 2021 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 27 Apr 2021 EMA Approvals for Multiple Sclerosis Highlight Treatment Shortfalls While the EU saw rapid-fire approvals in the multiple sclerosis space last month, the innovations centered mostly on improving existing approaches. Which areas of multiple sclerosis treatment need more options? At the end of March, the EMA made key decisions on three treatments for multiple sclerosis (MS), a chronic neurodegenerative disease affecting 2.5 million people […] April 27, 2021 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 11 Jan 2021 The 21 European Biotech Companies To Watch in 2021 As we enter 2021, the biotech industry is already bustling with activity. Here’s a list of 21 European biotech companies likely to make a big splash in the biotechnology sector over the next year. There were many memorable moments for the European biotech industry in 2020. The Covid-19 pandemic took over the media and many […] January 11, 2021 - 11 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 Dec 2020 A Year to Remember: The Biggest European Biotech News in 2020 The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled through. Let’s look back at some of the top moments in the last 12 months. After the many drug approvals, startup foundations, and venture capital highs we saw in 2019, it looked like 2020 was going to be a comfortable […] December 28, 2020 - 12 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jun 2020 AbbVie and Genmab Strike €3.4B Immuno-Oncology Megadeal AbbVie and Genmab have announced a €3.4B collaboration deal that ranks as the second biggest strategic alliance in European biotech in 2020. The partners aim to commercialize three phase I-stage antibody drugs for undisclosed types of solid and liquid cancer. Upfront, the US AbbVie will pay the Danish biotech €659M, with up to €2.77B available […] June 11, 2020 - 3 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 17 Sep 2019 European Biotechs Showcase Multiple Sclerosis Treatments in Stockholm Genmab, GeNeuro and other companies presented their latest data on next-generation treatments for multiple sclerosis at a conference in Stockholm. The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) gathered experts and companies working on multiple sclerosis in Sweden this year. Companies such as Genmab and GeNeuro revealed the progress of their treatments, […] September 17, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email